Présentation de l'entreprise
PRF Technologies Ltd. operates as a clinical stage specialty pharmaceutical entity dedicated to the reformulation of established therapeutics, with a specific operational focus on delivering extended post-surgical pain relief within the Israeli market. The company develops PRF-110, a viscous clear oil-based solution designed for direct instillation into surgical sites to manage pain recovery. This business falls under the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry, which typically involves high regulatory hurdles and a focus on niche therapeutic areas rather than broad consumer markets. The company's total market capitalization is valued at $1.98M, while its trailing twelve-month revenue stands at $17,000, and the precise employee count is not disclosed in available data. These valuation and revenue figures indicate that PRF Technologies is a micro-cap enterprise operating with a very small revenue base, suggesting it is in an early-stage development phase where capital allocation is heavily weighted toward research and clinical trials rather than commercial scale-up or established market share generation.
Santé financière
The financial performance for the trailing twelve months reveals a revenue of $17,000, a net income of -$4,838,000, and an EBITDA of -$4,348,000. The substantial disparity between the negligible revenue of $17,000 and the significant net loss of -$4,838,000 highlights an extremely fragile cost structure where operating expenses vastly outweigh any income generated from sales. The free cash flow is reported at -$2,002,250, indicating that the company is burning cash at a rapid pace, which severely limits its current financial flexibility and necessitates reliance on external financing or existing cash reserves to sustain operations. Margin analysis shows a gross margin of 0.0%, an operating margin of -16200.0%, and a profit margin of 0.0%, all of which reflect a company that has not yet achieved commercial profitability or positive gross contribution from its sales. The balance sheet holds $4.14M in cash against only $21,000 in debt, resulting in a debt-to-equity ratio of 0.23, which suggests the company is currently unleveraged and not utilizing significant debt to finance its activities. Liquidity is assessed via a current ratio of 1.78, indicating that the company possesses sufficient current assets to cover its short-term liabilities, though the magnitude of this buffer is constrained by the overall scale of the business. Return on Equity is -90.4% and Return on Assets is -38.7%, metrics that demonstrate management is currently generating negative returns on the capital invested, a common characteristic of clinical-stage biopharmaceuticals but one that signals an inability to produce shareholder value from existing assets at this stage.
Évaluation de la valorisation
Valuation metrics present a complex picture due to the absence of traditional profitability measures, with a trailing P/E ratio listed as N/A and a forward P/E of -0.19. The negative forward P/E implies that the market is pricing in a trajectory where earnings are expected to be negative in the near term, rendering traditional earnings-based valuation multiples inapplicable for assessing value. The price-to-book ratio stands at 0.23, indicating that the company's market value is trading at a significant discount to its book value, a phenomenon often seen in speculative biotech stocks where the market prices in high risk of failure. Alternative valuation multiples such as the price-to-sales ratio of 116.25 and an EV/EBITDA of 0.32 further illustrate the disconnect between current market price and operational reality, suggesting the market is paying a high premium for a very small sales base relative to the lack of earnings. The stock has a 52-week high of $17.95 and a 52-week low of $1.80, placing the current market position within a wide volatility range that reflects the speculative nature of the asset. With a beta of 0.71, the stock exhibits price volatility that is lower than the broader market average, suggesting it may be less sensitive to general market movements despite its micro-cap status.
Growth & Income
The growth profile is characterized by unavailable revenue growth and earnings growth rates for the year-over-year period, as both figures are listed as N/A. The absence of positive growth data combined with negative earnings implies that the company is not yet in a phase of scaling earnings faster than revenue, as no revenue exists to scale from. Regarding income distribution, the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Since the company does not distribute cash to shareholders, the implied strategy is to retain all available resources, including the $4.14M in cash, to fund ongoing clinical development and research efforts rather than rewarding shareholders with income. The overall growth and income profile is defined by a total lack of current commercial traction and income generation, relying entirely on the depletion of cash reserves to bridge the gap to potential future product approvals.